We want to capture some of the major achievements of students and postdocs who trained at the MRC Protein Phosphorylation and Ubiquitylation Unit (MRC PPU), and have created a new feature on our website the 'MRC PPU Alumni Interview'. These interviews, conducted by Hazel Lambert a well-known science writer, will reveal what our alumni are doing now, what makes them tick, and they'll share their insight and reflections regarding their time in the MRC PPU.
One of the most important missions of the MRC PPU is to recruit the most driven, talented, creative researchers in the world and provide them with an extraordinary research training experience while deciphering phosphorylation and ubiquitylation biology. The success of our alumni suggest we do just this.
In the first interview of this series Darren Cross an ex-MRC PPU PhD student in the 1990's now a Principal Scientist at AstraZeneca, discusses the key role he recently played in initiating and leading the discovery phase of a new anti-cancer drug called Tagrisso. This project broke AstraZeneca records, with Tagrisso being the fastest drug to go through clinical evaluation.
Click the new MRC PPU Alumni Interview icon on the top of our website, or here to read the interview.
One of the most important missions of the MRC PPU is to recruit the most driven, talented, creative researchers in the world and provide them with an extraordinary research training experience while deciphering phosphorylation and ubiquitylation biology. The success of our alumni suggest we do just this.
In the first interview of this series Darren Cross an ex-MRC PPU PhD student in the 1990's now a Principal Scientist at AstraZeneca, discusses the key role he recently played in initiating and leading the discovery phase of a new anti-cancer drug called Tagrisso. This project broke AstraZeneca records, with Tagrisso being the fastest drug to go through clinical evaluation.
Click the new MRC PPU Alumni Interview icon on the top of our website, or here to read the interview.